C
Christopher R. Vakoc
Researcher at Cold Spring Harbor Laboratory
Publications - 153
Citations - 21315
Christopher R. Vakoc is an academic researcher from Cold Spring Harbor Laboratory. The author has contributed to research in topics: Transcription factor & Chromatin. The author has an hindex of 52, co-authored 132 publications receiving 17071 citations. Previous affiliations of Christopher R. Vakoc include University of Pennsylvania & Watson School of Biological Sciences.
Papers
More filters
Journal ArticleDOI
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake Delmore,Ghayas C Issa,Madeleine E. Lemieux,Peter B. Rahl,Junwei Shi,Hannah M. Jacobs,Efstathios Kastritis,Timothy Gilpatrick,Ronald M. Paranal,Jun Qi,Marta Chesi,Anna C. Schinzel,Michael R. McKeown,Timothy P. Heffernan,Christopher R. Vakoc,P. Leif Bergsagel,Irene M. Ghobrial,Paul G. Richardson,Richard A. Young,William C. Hahn,William C. Hahn,Kenneth C. Anderson,Andrew L. Kung,James E. Bradner,Constantine S. Mitsiades +24 more
TL;DR: In this paper, a small-molecule bromodomain inhibitor, JQ1, was used to identify BET proteins as regulatory factors for c-Myc oncoprotein.
Journal ArticleDOI
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Jakob Lovén,Heather A. Hoke,Charles Y. Lin,Charles Y. Lin,Ashley Lau,David A. Orlando,Christopher R. Vakoc,James E. Bradner,Tong Ihn Lee,Richard A. Young +9 more
TL;DR: This work investigates how inhibition of the widely expressed transcriptional coactivator BRD4 leads to selective inhibition ofThe MYC oncogene in multiple myeloma (MM), and finds that super-enhancers were found at key oncogenic drivers in many other tumor cells.
Journal ArticleDOI
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber,Junwei Shi,Junwei Shi,Eric Wang,Amy R. Rappaport,Amy R. Rappaport,Harald Herrmann,Edward Allan R. Sison,Daniel Magoon,Jun Qi,Katharina Blatt,Mark Wunderlich,Meredith J. Taylor,Christopher Johns,Agustin Chicas,James C. Mulloy,Scott C. Kogan,Patrick Brown,Peter Valent,James E. Bradner,Scott W. Lowe,Scott W. Lowe,Scott W. Lowe,Christopher R. Vakoc +23 more
TL;DR: The results establish small-molecule inhibition of Brd4 as a promising therapeutic strategy in AML and, potentially, other cancers, and highlight the utility of RNA interference screening for revealing epigenetic vulnerabilities that can be exploited for direct pharmacological intervention.
Journal ArticleDOI
Histone H3 Lysine 9 Methylation and HP1γ Are Associated with Transcription Elongation through Mammalian Chromatin
TL;DR: It is shown that H3K9 di- and trimethylation occur in the transcribed region of active genes in mammalian chromatin and this modification is dynamic, as it increases during activation of transcription and is rapidly removed upon gene repression.
Journal ArticleDOI
Promoter-bound METTL3 maintains myeloid leukaemia by m 6 A-dependent translation control
Isaia Barbieri,Konstantinos Tzelepis,Luca Pandolfini,Junwei Shi,Gonzalo Millán-Zambrano,Samuel Robson,Demetrios Aspris,Valentina Migliori,Andrew J. Bannister,Namshik Han,Etienne De Braekeleer,Hannes Ponstingl,Alan G. Hendrick,Christopher R. Vakoc,George S. Vassiliou,Tony Kouzarides +15 more
TL;DR: Together, these data define METTL3 as a regulator of a chromatin-based pathway that is necessary for maintenance of the leukaemic state and identify this enzyme as a potential therapeutic target for acute myeloid leukaemia.